Top Markets
Coin of the day
Clarity Pharmaceuticals Ltd Clarity Pharmaceuticals Ltd

Clarity Pharmaceuticals Ltd

CU6
Rank in Stocks #11775
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company,... Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The company’s lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer. The company was incorporated in 2010 and is based in Sydney, Australia.
Share Price
$1.77
Last synced: 2026-08-28
Market Cap
$660.45M
Change (1 day)
7.26%
Change (1 year)
-9.15%
Country
AU
Trade Clarity Pharmaceuticals Ltd (CU6)

Category

Stock split history for Clarity Pharmaceuticals Ltd (CU6)
Clarity Pharmaceuticals Ltd stock (symbol: CU6) underwent a total of 0 stock splits.
The most recent stock split occurred on Aug 30, 2026.
One CU6 share bought prior to Aug 30, 2026 would equal to 0 CU6 shares today.
Stock split list
Year Split Multiple Cumulative Multiple
Not enough data for the provided dates.
Stock splits for similar companies or competitors